When a clinical trial closes, is cancelled, transfers, or loses funding, a clinical research associate (CRA) employed through an Employer of Record (EOR) has three employment outcomes to evaluate. The sponsor or contract research organization (CRO) should assess them with the local legal employer:
The outcome comes from the employment agreement, the employee's location, available work, and local law. A study status field cannot settle those facts by itself.
Sponsors and CROs should resist choosing the employee's last day from a last participant visit, site closure notice, cancellation email, or budget stop. Those events start the review. The remaining work, employment agreement, employee location, and local process complete it.
Use three dates instead of one “trial end”
A clean decision separates three dates:
- The operational study date. This might be a last participant visit, a site closure decision, a suspension, a funding stop, or a transfer to another sponsor or CRO.
- The CRA assignment-work date. This is when the person's allocated closeout, monitoring follow-up, record reconciliation, and handover work is complete or has moved to a qualified owner.
- The employment date. This is when current employment continues, valid new terms take effect, or a lawful exit becomes effective.
The second date is where the CRA role changes the employment decision. ICH E6(R3), the international Good Clinical Practice guideline adopted by ICH at Step 4 in January 2025, treats monitoring as work across the clinical trial life cycle. Site closeout activity includes confirming arrangements for essential-record retention and final accountability for the investigational product. Monitoring reports can also leave findings that require action and documented resolution. See the ICH closeout guidance.
ICH guidance describes clinical responsibilities. Its legal effect depends on adoption and applicable rules in the trial jurisdiction, and it does not govern the employment relationship.
That evidence does not require a sponsor or CRO to retain one CRA indefinitely. It requires clinical owners to identify what remains, who is qualified to do it, and how the transfer will be documented. Employment can then follow the correct work date and local process.
Outcome 1: continue the current employment
Continuation is often the simplest path when the employment agreement defines a portfolio CRA role and one closing study is only part of the workload.
Suppose a CRA supports three trials. One moves into closeout while two remain active. Clinical operations can update the allocation, reporting line, monitoring plan responsibilities, and system permissions while the EOR continues the existing employment arrangement. This path still needs a contract check. A broadly written CRA role may support the change, while a narrow agreement tied to one study may not.
Continuation can also cover genuine closeout work. The sponsor or CRO should name the remaining activities, expected hours, owner, deadlines, systems, and funding. Calling the period “closeout” adds little unless the employee has real assigned work.
A funded interval is a continuation decision
A funded interval can make sense when the CRA has a defined closeout tail or the next study is sufficiently certain. It is a commercial choice implemented through the existing employment relationship, rather than a universal legal status.
Build the cost through the expected decision date. Include:
- salary, statutory employer charges, benefits, and EOR fees;
- closeout travel or site expense that still belongs to the assigned work;
- training and other CRA duties that will actually be performed;
- overlap with a qualified replacement or handover owner;
- contract amendment, consultation, local advice, translation, immigration, or benefit work where applicable;
- the cost of extending the interval if the next study slips again.
Then compare that amount with the timing and full cost of a lawful exit, followed by later recruitment and onboarding. The comparison should use actual country and contract inputs. There is no useful global notice or severance rate for this decision.
Borderless's public pages explain its general EOR and payroll model. They do not confirm support for a paid interval with no active study, or the treatment of that interval in a particular country. Ask the provider to confirm the exact arrangement, benefits, payroll, customer commitment, and end options before relying on it.
Outcome 2: separate work allocation from a contract change
Moving a CRA from one protocol to another can look routine inside clinical operations. The employment consequences depend on what changes.
A new study may fit the current role when the duties, pay, hours, work location, travel expectations, status, and employer stay within the existing agreement. Even then, the sponsor or CRO should confirm that the CRA is qualified and trained for the allocated work. ICH E6(R3) says sponsors should use appropriately qualified individuals for assigned trial activities throughout the trial process.
A proposed move needs closer review when it changes a material term. Examples include reduced pay, different hours, a new country of work, materially heavier travel, a lower-status role, or duties outside the agreed CRA scope. The client should send the proposed change to the EOR before discussing it as a settled outcome with the employee. The EOR, as legal employer, can identify the local agreement, consultation, documentation, payroll, benefit, and notice requirements.
Unpaid leave, a salary reduction, and automatic reassignment are not default gap solutions. Their availability depends on the employment agreement and local law.
Outcome 3: a locally lawful exit remains available
An exit may be the appropriate result when closeout is complete or transferred, no suitable work is available, and the business cannot fund continued employment. It may also follow a valid fixed-term endpoint.
The sponsor or CRO should provide the business facts and desired timing. The EOR, as the local legal employer, should determine the valid route and perform the employment action. The review may need to cover the contract type, reason, consultation or selection process, notice, accrued leave, final pay, locally required severance, benefits, immigration, and protected-status issues.
Clinical work should shape the sequence. It does not replace the employment process. A sponsor can move remaining activities to another qualified person and preserve records in controlled repositories. A former employee should not become the informal keeper of trial knowledge because the handover was rushed.
CRA closeout facts that can change paid time and access
The closeout review should focus on facts that alter employment timing or execution:
ICH E6(R3) keeps ultimate responsibility for sponsor trial activities with the sponsor when activities move to a service provider. It also requires oversight of important transferred activities. The CRA's employer arrangement does not absorb that accountability. See the sponsor provisions.
Records follow the same division of responsibility. ICH calls for arrangements covering access and management during the trial and retention after completion. The sponsor and investigator or institution retain the essential records needed for their respective responsibilities. The EMA TMF guideline likewise places continuing responsibilities with the sponsor and investigator or institution, requires controlled access, and calls for a documented transfer of TMF ownership.
The US rules provide a concrete example. For drug trials under an investigational new drug application, 21 CFR 312.57 assigns sponsor recordkeeping, while 21 CFR 312.62 assigns investigator records and unused-drug disposition. These are sponsor and investigator duties. They do not turn the CRA into the personal archive.
Who decides, and who acts?
Responsibility becomes easier to manage when each party has one clear lane.
If the CRO is the EOR's client, it may make the workforce and budget decision. The sponsor still retains the clinical accountability that ICH assigns to the sponsor for transferred sponsor activities.
A seven-step sequence for the decision
1. Define the trigger
Record what changed, when it changed, and whether it affects one site, one study, or the person's full workload. Use a decision date separate from the operational event date.
2. Inventory the remaining work
List closeout, monitoring-report follow-up, records, investigational-product accountability support, participant follow-up support, site communications, and other studies. Assign an owner and expected completion or transfer date to each item.
3. Read the employment instrument
Confirm the legal employer, employee location, indefinite or fixed-term status, role scope, study references, hours, pay, work location, mobility or flexibility language, and early-termination terms. Check collective terms and immigration conditions where relevant.
4. Select a proposed path
Choose continued employment, reassignment or change, or exit using actual work and budget. Continued employment can include funded closeout or an approved interval. Keep alternatives available until the local employer validates the path.
5. Align the two workstreams
Clinical operations should set the handover and access plan. The EOR should set the employment steps and effective date. Each plan should name the dependency on the other.
6. Price the full path
Include employment cost through the effective date, remaining trial work, overlap, local process, and a delay scenario. A cheaper headline choice can become expensive when it ignores closeout or a failed next-study start.
7. Document and execute
Use the employer's required documents and communications. Record the work transfer, responsible clinical owners, system-access changes, asset return, final pay inputs, and the point of contact for later questions.
UK illustration: a trial-related fixed term can matter
This example applies only to the United Kingdom.
GOV.UK recognises a fixed-term contract that ends on a date or completion of a specific task in its contract definition. Its ending guidance also says non-renewal is treated as a dismissal and that an early end depends on the contract terms.
For a UK CRA, this means a clearly drafted trial-related endpoint may matter. The employer still needs to establish what event the contract names, whether the work has reached that point, whether employment continued beyond it, and which dismissal or redundancy rules apply. A move to less favourable terms raises a separate contract-change question. GOV.UK change guidance calls for agreed changes to be documented and says flexibility clauses support only reasonable changes.
The result could be continuation, agreement on another study, non-renewal at a valid endpoint, or another lawful exit route. The deeper Borderless UK termination guide covers the broader country context. Apply local review to the current contract and facts.
Frequently asked questions
Does an EOR-employed CRA's contract end when the trial ends?
The employment outcome depends on the contract and local law. A trial event starts the review. Check whether the CRA has remaining closeout work, supports other studies, holds an indefinite or fixed-term agreement, and has a trial-related endpoint in the contract.
Can the CRA move directly to the next study?
Yes, when the new work is available, the CRA is qualified, and the move fits the existing agreement or a valid change process. Confirm training, duties, pay, hours, travel, work location, systems, and manager before treating the move as complete.
Who handles a termination in an EOR arrangement?
The sponsor or CRO supplies the business rationale, timing request, and clinical transition facts. The EOR, as legal employer, validates and performs the local employment process. Clinical accountability and records duties remain with the sponsor and investigator or institution according to their roles.
When should the CRA lose access to trial systems?
Clinical operations and information-security owners should set the access plan around the last authorised activity, handover, and employment process. Security, legal, safety, or employment facts may require immediate revocation. In that case, preserve the records and audit trail, then reassign open work through authorised owners. Former-worker credentials should not remain active. If work must continue after a proposed date, revise the plan through an authorised employment and access arrangement.
